Redalsomatropin Biosimilar – Anti-GH-N fusion protein – Research Grade

Title: Introduction to Redalsomatropin Biosimilar – A Revolutionary Therapeutic Protein

Redalsomatropin Biosimilar is a groundbreaking therapeutic protein that has been developed as a biosimilar version of the human growth hormone (GH). It is a fusion protein that combines the anti-GH activity with the natural activity of GH-N, making it a highly effective therapeutic agent. In this article, we will explore the structure, activity, and potential applications of Redalsomatropin Biosimilar in the field of medicine.

Title: Structure of Redalsomatropin Biosimilar

Redalsomatropin Biosimilar is a fusion protein composed of two distinct components – the anti-GH and GH-N. The anti-GH component is derived from a naturally occurring protein that has the ability to bind to the GH receptor and inhibit its activity. On the other hand, the GH-N component is a fragment of the human growth hormone that is responsible for its natural activity in the body. The two components are linked together using recombinant DNA technology to create a single, stable fusion protein.

Title: Activity of Redalsomatropin Biosimilar

Redalsomatropin Biosimilar exhibits a dual activity due to the presence of both anti-GH and GH-N components. The anti-GH component binds to the GH receptor and blocks its activity, thereby reducing the levels of GH in the body. This is particularly beneficial in conditions where excess GH is produced, such as acromegaly. The GH-N component, on the other hand, mimics the natural activity of GH and promotes growth and development in the body. This makes Redalsomatropin Biosimilar an ideal therapeutic protein for treating growth hormone deficiency and other related disorders.

Title: Therapeutic Target of Redalsomatropin Biosimilar

The therapeutic target of Redalsomatropin Biosimilar is the GH receptor, which is present on the surface of cells in various tissues and organs. By targeting this receptor, Redalsomatropin Biosimilar is able to exert its anti-GH and GH-N activity, making it a highly effective therapeutic agent for a range of conditions related to GH imbalance. The ability to target the GH receptor also makes Redalsomatropin Biosimilar a potential treatment for other conditions such as Turner syndrome, Prader-Willi syndrome, and short stature in children.

Title: Applications of Redalsomatropin Biosimilar

Redalsomatropin Biosimilar has a wide range of potential applications in the field of medicine. It can be used to treat conditions such as acromegaly, growth hormone deficiency, Turner syndrome, and Prader-Willi syndrome. In addition, it has shown promising results in treating short stature in children, especially those with idiopathic short stature. Redalsomatropin Biosimilar can also be used in combination with other therapeutic proteins for the treatment of various disorders. Furthermore, its research grade quality makes it an ideal tool for studying the role of GH in various physiological processes.

Title: Conclusion

In conclusion, Redalsomatropin Biosimilar is a revolutionary therapeutic protein that combines the anti-GH activity with the natural activity of GH-N. Its unique structure and dual activity make it a highly effective treatment option for a range of conditions related to GH imbalance. With its potential applications in various disorders and research grade quality, Redalsomatropin Biosimilar is set to make a significant impact in the field of medicine.

ProteoGenix catalogue number PX-TA2234. For research use only.

Target: Redalsomatropin Biosimilar – Anti-GH-N fusion protein – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet